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Pharmacology of Intracisternal or Intrathecal Glycine, Muscimol, 
and Baclofen in Strychnine-induced Thermal Hyperalgesia of Mice
Glycine and γ-aminobutyric acid (GABA) are localized and released by the same 
interneurons in the spinal cord. Although the effects of glycine and GABA on analgesia are 
well known, little is known about the effect of GABA in strychnine-induced hyperalgesia. 
To investigate the effect of GABA and the role of the glycine receptor in thermal 
hyperalgesia, we designed an experiment involving the injection of muscimol (a GABAA 
receptor agonist), baclofen (a GABAB receptor agonist) or glycine with strychnine 
(strychnine sensitive glycine receptor antagonist). Glycine, muscimol, or baclofen with 
strychnine was injected into the cisterna magna or lumbar subarachnoidal spaces of mice. 
The effects of treatment on strychnine-induced heat hyperalgesia were observed using the 
pain threshold index via the hot plate test. The dosages of experimental drugs and 
strychnine we chose had no effects on motor behavior in conscious mice. Intracisternal or 
intrathecal administration of strychnine produced thermal hyperalgesia in mice. Glycine 
antagonize the effects of strychnine, whereas, muscimol or baclofen does not. Our results 
indicate that glycine has anti-thermal hyperalgesic properties in vivo; and GABA receptor 
agonists may lack the binding abilities of glycine receptor antagonists with their sites in the 
central nervous system.
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INTRODUCTION
Gamma-aminobutyric acid (GABA) and glycine are important 
inhibitory neurotransmitters in the mammalian central nervous 
system (CNS) (1). GABA and glycine are co-localized in interneu-
rons in spinal laminae I-III (2) and are released from the same 
interneurons (3).
  The temporary removal of spinal glycinergic inhibition by 
administration of intrathecal strychnine (strychnine sensitive 
glycine receptor antagonist) disturbs sensations and produces 
an effect resembling neuropathic pain. Strychnine treatments 
are used to investigate potential analgesics (4), particularly an-
algesics that directly or indirectly enhance the glycinergic me-
diation of nociceptive information (5). We hypothesized that if 
GABA and glycine are co-released from the same interneurons 
and GABA agonists act at GABA and glycine receptors to mod-
ulate nociceptive transmission via distinct but complementary 
mechanisms, GABA agonists might inhibit strychnine-induced 
nociception. In previous papers, we demonstrated that admin-
istration of intrathecal glycine, taurine, and muscimol antago-
nized bicuculline-induced thermal hyperalgesia (6) and intra-
thecal muscimol did not antagonize strychnine-induced allo-
dynia or thermal hyperalgesia (7) in vivo. However, the nature 
of the interaction between glycine and GABA during sensory 
modulation remains unclear.
  We undertook the present study with following objectives: 
first, to determine whether central administration of strychnine 
produce thermal hyperalgesia; second, to determine whether 
muscimol (GABAA receptor agonist), baclofen (GABAB receptor 
agonist), or glycine antagonizes strychnine-induced thermal 
hyperalgesia.
 
MATERIALS AND METHODS
Animals
This study was conducted after obtaining approval from the An-
imal Care Committee of Korea University and in accordance 
with the guidelines of the Ethics Committee of the International 
Association for the Study of Pain. Male ICR mice weighing 23-
27 g were housed one per cage before experiments in an envi-
ronmentally controlled room (22°C ± 2°C, relative humidity 
55% ± 5%) under a 12:12 hr light cycle (lights on at 7:00 am) with 
free access to food and water.
Drugs
Solutions were prepared in artificial cerebrospinal fluid (aCSF) Lee IO, et al.  •  GABA in Strychnine Induced Hyperalgesia
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containing (in mM/L): 124 NaCl, 26 NaHCO3, 1.25 NaH2PO4, 2.5 
KCl, 2 MgCl2, 2 CaCl2, and 10 dextrose. The pH of the solution was 
7.3-7.4 and its average osmolality was ~300 mOsm. Drugs were 
dissolved in sterile saline on experimental days and kept on ice 
until used. Immediately prior to use, drugs were diluted to the 
required concentrations with aCSF. Muscimol, baclofen, and 
glycine were purchased from Sigma (St. Louis, MO, USA) and 
sevoflurane was purchased from Abbott Laboratories (Queen-
borough, Kent, UK).
Intracisternal injections
Anesthesia was induced using 4% sevoflurane in air in a 500 mL 
induction chamber. A rubber facemask was used for anesthetic 
maintenance (sevoflurane 4% through a Mapleson D circuit) and 
to immobilize heads. In addition, mice were placed in a holder 
molded from modeling clay to fit the body. A space was molded 
in the posterior neck area to allow the region between the occiput 
and atlas to be palpated and to enable the injection to be made. 
Intracisternal injections were performed using a 25 µL Hamil-
ton syringe (Hamilton Co., NV, USA) attached to a 27G stainless 
steel needle, the tip of which was modified with a stopper to en-
sure an insertion depth of 2.4 mm. The needle was carefully ad-
vanced to the cisterna magna and after the injection was made 
the syringe was held in position for a few seconds before gradu-
ally being removed to avoid drug outflow along the needle tract. 
Injection sites were verified by injecting a similar volume of 1% 
methylene blue solution and confirming the distribution of dye 
in the cisternal space. Throughout the experiment, the dye was 
observed throughout the cisterna magna and reached the occip-
ital surface of the brain and the upper cervical portion of the spi-
nal cord. The experimenter was trained using dye injections prior 
to beginning the experiments and achieved an accuracy of > 98% 
in test mice. One experimenter performed all procedure. The 
entire injection procedure, including anesthesia, took about less 
than three minutes per animal. Spontaneous face scratching, 
backward folding of the ears, eye squinting or markedly increased 
responsiveness to light touch in trigeminal areas such as head 
withdrawal, intense face scratching were observed after injec-
tion of strychnine.
Intrathecal injection
All intrathecal injections were made at the L5-L6 intervertebral 
space using a 30 gauge 0.5 inch needle mounted on a 25 µL Ham-
ilton syringe, as previously described by Hylden and Wilcox (8). 
Injection sites were verified by injecting a similar volume of 1% 
methylene blue solution and determining the distribution of 
the dye in the spinal cord. The dye was distributed rostrally and 
caudally but over a short distance (less than 1 cm) and no dye 
was found in the brain in all animals. The experimenter was sim-
ilarly trained using dye prior to the experiments and achieved 
an accuracy of  > 95% in test mice. One experimenter performed 
all procedure. The entire intrathecal injection procedure, includ-
ing handling, also took about less than three minutes per ani-
mal. Spontaneous tail biting, tail flick or light touch-evoked al-
lodynia of the hind feet and tail were observed after injecting 
mice with strychnine.
Experimental protocol
To examine the effects of different strychnine doses, 5 µL of 
strychnine at concentrations of 50 (0.083575 µg), 100 (0.16715 
µg), 200 (0.3344 µg), or 400 μM (0.6688 µg) were injected intra-
cisternally or intrathecally. Mice that received > 0.08 µg showed 
allodynia. Two of the four mice treated with 0.08 µg of strych-
nine failed to respond to a light touch. On the other hand, 0.33 
µg strychnine induced touch-evoked allodynia in a predictable 
manner. One of six mice treated with strychnine 0.33 µg intra-
cisternally showed a dyskinetic behavior or four of the four mice 
treated with strychnine 0.66 µg intracisternally showed a convul-
sive behavior (body rollover, loss of postural control, falling, mo-
tor arrest with a myoclonic jerk, frequent dyskinesia) (9). Accord-
ingly, we used 0.16 µg of strychnine to induce pain in all subse-
quent experiments.
  To determine muscimol doses, we injected 5 µL at concentra-
tions of 0.025 (0.0142625 µg), 0.05 (0.028525 µg), 0.25 (0.142625 
µg), 0.5 (0.28525 µg), 1 (0.5705) or 5 (2.8525 µg) mM. Mice that 
received 0.28 µg intracisternally were sedated for more than 4 
min or showed intermittent dyskinetic hyperactivity; we were 
unable to perform the hot plate test on these mice. Mice admin-
istered 2.8 µg of muscimol intrathecally showed paresis of both 
hindlimbs for more than 2 hr. Finally, we used muscimol doses 
of 0.01, 0.02, and 0.1 µg for the subsequent experimental group.
  To determine baclofen doses, we injected 5 µL at concentra-
tions of 0.01 (0.010685 µg), 0.05 (0.053425 µg), 0.1 (0.10685 µg), 
or 1 (1.0685 µg) mM. Mice that received 0.05 µg intracisternally 
were sedated for more than 4 min; we were unable to perform 
the hot plate test on these mice. Mice administered 1.06 µg of 
baclofen intrathecally showed paresis of both hindlimbs for more 
than 1 hr. Finally, we used baclofen doses of 0.001, 0.002, and 
0.01 µg for the subsequent experimental group.
  Similarly, preliminary experiments indicated that analgesic 
doses of 25 µg for glycine were optimal for both intracisternal 
and intrathecal injections. The dosages of glycine used had no 
effects on motor behavior in conscious mice.
Study design
All experiments were blinded and randomized. The experimen-
ter who injected the drug and the observer were unaware of treat-
ment details. Drug and control solutions were injected in a ran-
dom, computer-generated order (http://www.randomizer.org). 
Each animal was subjected to one treatment only. Hot plate test 
sessions were conducted for 40 min after drug injections. Exper-
iments were conducted between 9:00 am and 16:00 pm in a qui-Lee IO, et al.  •  GABA in Strychnine Induced Hyperalgesia
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  Control mice were administered 5 µL of strychnine (the stry-
chnine groups; n = 8) or aCSF vehicle (the vehicle controls; n =  
8) only. Experimental groups were divided randomly into sub-
groups, namely, vehicle control (n = 8); glycine (5, 10, 25 µg in-
tracisternally or intrathecally; n = 8, per dosage); muscimol (0.01, 
0.02, 0.1 µg intracisternally or intrathecally; n = 8, per dosage); 
and baclofen (0.001, 0.002, 0.01 µg intracisternally or intrathe-
cally; n = 8, per dosage). Each mouse in the experimental groups 
received strychnine along with one of the drugs listed above. In 
experiments exploring the combined effects of the drugs, the 
drugs were co-administered intracisternally or intrathecally to 
ensure co-localization and to minimize injection volumes. After 
injections, the mice were placed on a clear glass plate for the hot 
plate test. The timing of the hot plate test was started after com-
pletion of injections.
Behavioral tests
To assess whether drugs induced sedation or motor impairment, 
a naïve observer utilized a five-point scale to evaluate posture 5 
min after drug injection (10). The scale was as follows: 0 = nor-
mal posture, rearing and grooming; 1 = moderate atonia and 
ataxia; 2 = weight support, but severe ataxia; 3 = muscle tone 
but not weight support and 4 = flaccid atonia, fully immobilized. 
The level of sedation of each mouse was assessed by testing the 
animal’s response to passive head movement on stimulation of 
the vibrissae (11). The scale was as follows: 0 = awake; active ex-
ploring, brisk head response; 1 = slightly drowsy, not actively 
exploring but easily stimulated by manipulating head or vibris-
sae; 2 = drowsy, responding only to vigorous manipulation of 
head or vibrissae; 3 = unresponsive to head manipulation. The 
animals were observed for 45 min after drug injection.
Rotarod test
In a rotarod test, the ability of mice to stay on a rotating rod was 
used to assess motor performance by a rotarod. The rotarod con-
sisted of a rotating rod (2.8 cm diameter) and individual com-
partments for each mouse. Mice were selected for their ability 
to remain on the rod (5 rpm) for two consecutive 5 min trials 
separated by a 5 min rest period. For all experiments two con-
trol trials obtained 6 min apart preceded the drug injection. Each 
mouse was then given trials at 6 min-intervals after the drug in-
jection. If a mouse fell before 5 min, his failure time was recorded 
and the results were averaged to obtain a single value for each 
group.
Hot plate test
Mice were allowed to acclimate within an acrylic enclosure on 
a clear glass plate before each experiment. A radiant heat source 
was then focused onto the plantar surface of a hindpaw. The test 
involved placing a mouse on a hot plate maintained at 55ºC and 
recording the time taken to first response (foot licking, jumping, 
or rapidly removing paws), as described by Minami et al. (12). A 
timer stopped automatically when withdrawal of the paw was 
detected by a photodetector (a cut-off value of 30 sec was used 
to prevent tissue damage). Response times were measured twice 
at 3 min intervals and mean values were recorded as pain thresh-
olds. Basal pain thresholds were measured before drug admin-
istration (time = 0). Responses were observed at 5, 15, 25, 35 and 
45 min after drug injection. These times were chosen based on 
the results of preliminary studies, which showed that the hot plate 
response peaked between 5 and 25 min after injecting strych-
nine intracisternally. In the preliminary study, we also knew that 
the intrathecal strychnine 0.3 µg showed a significant hot plate 
response for 60 min after injection (7). In terms of drug localiza-
tion, we believe that the intrathecal route is better than the intra-
cisternal route because drug dissipation is probably the main 
cause of the transient effect in mobile animals, making it more 
likely for the drugs to diffuse to the brainstem and more difficult 
to localize their actions on the spinal cord. Therefore we chose 
a dose of strychnine 0.16 µg and an observation time of 45 min 
after injection for the purpose of comparison between the intra-
cisternal and intrathecal effect of drug in the present study.
  For analysis purposes, all response latencies were expressed 
as hot plate test pain indices (HPPI) where:
  HPPI =
          Pain threshold by the hot plate test
      Basal pain threshold by the hot plate test
Statistical analysis
Behavioral results were analyzed using the binomial test. Hot 
plate test results were analyzed by ANOVA. Post hoc analysis was 
performed using Dunn’s test or Holm-Sidak methods. Student’s 
two-tailed test was used to compare two means. The level of sig-
nificance was set at 5% (P < 0.05). Data are presented as means 
± SEM. Statistical analysis was performed using SigmaStat 3.0 
(Systat Software Inc., Chicago, IL, USA).
 
RESULTS
Behavioral effects of experimental drugs
The behavioral effects of glycine, muscimol or baclofen at the 
injected doses were studied in an open field chamber. All mice 
scored 0 (0 = normal posture, rearing and grooming; see meth-
ods) during this test. Sedation scores of more than 1 (1 = slightly 
drowsy, not actively exploring but easily stimulated by manipu-
lating head or vibrissae; see methods) were not observed in any 
mice.
Rotarod test
The time fell from the rod of conscious mice was not affected by 
aCSF, glycine, muscimol, or baclofen (P > 0.05). The strychnine Lee IO, et al.  •  GABA in Strychnine Induced Hyperalgesia
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groups exhibited no effects on the time fell from the rod com-
pared with aCSF group (P > 0.05) (Table 1).
Effects of muscimol, baclofen, and glycine on strychnine 
induced heat hyperalgesia
The basal latencies of all conscious mice as observed by hot plate 
tests were similar before drug injection. Mice that received in-
tracisternal glycine (25 µg) alone had a higher HPPI at 15 min 
than at baseline (time = 0) and than vehicle controls at 15 min 
(P < 0.05). When given alone, intracisternal or intrathecal mus-
cimol or baclofen had no effect on the pain threshold index in 
the hot plate test at the doses tested (P > 0.05 vs vehicle controls) 
(data not shown).
  Intracisternal strychnine decreased the HPPI from 5 to 25 min 
(P < 0.05 vs vehicle controls). Intrathecal strychnine decreased 
the HPPI from 5 to 45 min (P < 0.05 vs vehicle controls). There 
were significant differences of the HPPI at 5 to 25 min and the 
Table 1. Effect of aCSF, strychnine, glycine, muscimol, baclofen on the falling time 
from the rotarod in conscious mice
Group
Intracisternal injection Intrathecal injection
Falling time (sec) Falling time (sec)
aCSF 266 ± 13 255 ± 14
Strychnine 245 ± 17 232 ± 31
Glycine 
   5 µg
   10 µg
   25 µg
 
235 ± 11
277 ± 14
243 ± 18
 
234 ± 16
273 ± 13
242 ± 16
Muscimol 
   0.01 µg
   0.02 µg
   0.1 µg 
 
244 ± 12
223 ± 15
246 ± 17
 
233 ± 13
258 ± 11
246 ± 16
Baclofen
   0.001 µg 
   0.002 µg 
   0.01 µg 
 
262 ± 18
264 ± 17
275 ± 10
 
243 ± 12
264 ± 17
232 ± 15
Data are expressed as the mean ± S.D. (n = 8 per group). aCSF, artificial cerebrospi-
nal fluid.
Fig. 1. Effect of strychnine or artificial cerebrospinal fluid (aCSF) on hot plate test pain index (HPPI). Strychnine (0.16715 µg) or aCSF was injected intracisternally (IC, A) or in-
trathecally (IT, B). Data are expressed as mean ± SEM. *P < 0.05 vs vehicle (aCSF) controls by the t-test; 
†P < 0.05 vs basal time point (time = 0) by repeated measures ANO-
VA (n = 8 mice per group).
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Fig. 2. Effect of glycine on HPPI in strychnine treated mice. Glycine (5, 10, and 25 µg) with strychnine (0. 16715 µg) was injected intracisternally (IC, A) or intrathecally (IT, B). 
Data are expressed as mean ± SEMs. *P < 0.05 vs the strychnine + aCSF group by two-way ANOVA, Dunn’s test, or the Holm-Sidak method (n = 8 mice per group). 
†P < 0.05 
vs. basal time point (time = 0) by repeated measures ANOVA (n = 8 mice per group).
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baseline value (time = 0) in the intrathecal strychnine group (P <  
0.05 vs baseline, time = 0) (Fig. 1).
  In drug + strychnine groups, glycine (intracisternally 25 µg or 
intrathecally 25 µg) increased the HPPI (P < 0.05 vs strychnine + 
aCSF group) (Fig. 2). In drug + strychnine groups, intracisternal 
or intrathecal muscimol or baclofen did not increase the HPPI 
(Figs. 3, 4).
  In the drug + strychnine group, intracisternal glycine (25 µg) 
increased the HPPI at 15 min (P < 0.05 vs baseline, time = 0) 
(Fig. 2A).
DISCUSSION
The present study demonstrates that glycine receptor antago-
nists produce thermal hyperalgesia, confirming the hypothesis 
that the loss of endogenous glycine tone leads to hyperalgesia. 
Muscimol or baclofen was ineffective to reduce strychnine-in-
duced thermal hyperalgesia. These results suggest that GABA 
lacks an antinociceptive effect on the strychnine induced ther-
mal hyperalgesia and an interaction between GABA and glycine 
receptors was insufficient to regulate anti-thermal hyperalgesia. 
  Glycine is important in the spinal processing of innocuous 
tactile information (13). Glycine is a selective modulator of non-
nociceptive input and the blockade of spinal glycinergic recep-
tors with strychnine yields allodynia. Therefore, previous stud-
ies have focused on strychnine-induced mechanical allodynia. 
Allodynia is triggered by input from Aβ fibers, rather than abnor-
mally sensitized C-fibers (14). In contrast, hyperalgesia arises 
from a decrease in the threshold of activation of nociceptive C-
fibers (15). According to previous studies, the loss of spinal strych-
nine sensitive inhibition augments development of thermal hy-
peralgesia by chronic nerve compression (16) and spinal glycine 
produces analgesia in thermal nociception (17). In the present 
study, we demonstrated that central strychnine produces ther-
mal hyperalgesia of hindfoot, which supports the hypothesis 
that the loss of glycine tone leads to not only allodynia but also 
Fig. 3. Effect of muscimol on HPPI in strychnine treated mice. Muscimol (0.01, 0.02, or 0.1 µg) with strychnine (0.16715 µg) was injected intracisternally (IC, A) or intrathecally 
(IT, B). Data are expressed as means ± SEMs (n = 8 mice per group). 
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Fig. 4. Effect of baclofen on HPPI in strychnine treated mice. Baclofen (0.001, 0.002, or 0.01 µg) with strychnine (0.16715 µg) was injected intracisternally (IC, A) or intrathe-
cally (IT, B). Data are expressed as means ± SEMs (n = 8 mice per group). 
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hyperalgesia.
  In previous studies, intracerebroventricular or intrathecal in-
jections of glycine significantly increased the pain threshold in-
dex in the hot plate test for 45 min after injection (17). We ob-
served slightly shorter duration of thermal antinociception, but 
we administered different doses of glycine than those used in the 
previous study. In our study we used 25 µg of glycine, while the 
previous study used 100 µg for analgesia. In the previous study, 
the researchers did not observe any abnormal behaviors such as 
sedation or dyskinesia, and they performed a motor test 10 min 
after injection, whereas we observed the sedative effect of intra-
cisternal glycine for more than 4 min if we injected more than 
25 µg in our preliminary experiment. We believe that the amounts 
of amino acids used in our study better allow experimenters to 
blindly assess heat hyperalgesia of the hindfoot after drug injec-
tion. The observed differences may be due to the different drug 
administration routes used as well as parameters checked. In 
previous studies, the drugs were injected intracerebroventricu-
larly (17), whereas we injected drugs intracisternally. As a wide-
spread inhibitory neurotransmitter, glycine invariably affects 
normal behavior, and therefore we think it is prudent to quanti-
fy glycine potency in producing motoric effects using the routes 
of administration used for the analgesia test. We observed that 
intracisternal, and not intrathecal, injection of glycine induced 
sedative effects according to the doses injected in preliminary 
tests (data not shown). Taken together, glycine and glycine recep-
tors play important roles in anti-hyperalgesic effects and these 
effects continue for less than one hour.
  GABA is densely localized in the spinal cord, where it appears 
to modulate both nociceptive and non-nociceptive neurotrans-
mission. GABA and glycine are co-localized in interneurons in 
lamina I-III of the dorsal horn. GABAA agonists such as musci-
mol and GABAB agonists like baclofen, when given intrathecal-
ly, significantly increase response latency in the tail flick and hot 
plate tests (18, 19). If glycine and GABA are released together into 
the synapse upon stimulation and if GABA and glycine affect 
distinct but complimentary inhibition of input in the spinal cord, 
then the pain arising from the blockade of spinal glycine recep-
tors should be attenuated by the concurrent activation of GABA 
receptors. However, in the present study, we could not demon-
strate that muscimol or baclofen, at a dose that does not affect 
the basal hot plate response, antagonizes strychnine-induced 
hyperalgesic response. These findings are not in agreement with 
our hypothesis that GABA and glycine are co-localized and mod-
ulate nociceptive transmission. Our findings are in agreement 
with previous studies (20, 21). However, contrary to our results, 
Balerio and Rubio reported that intraperitoneal baclofen (1-3 
mg/kg, rat) elicits a dose-dependent antinociceptive effect dur-
ing the hot plate test (22). Chung et al. (23) showed that intracere-
broventricular baclofen (5-10 ng) reduces the behavioral hyper-
algesic response induced by the formalin test in mice. Hammond 
and Drower reported that intrathecal muscimol (0.25 µg) or ba-
clofen (1 µg) increases tail flick or hot plate latencies in mice, re-
spectively (18). This discrepancy may be due differences in pain 
models, different drug administration sites or to different doses. 
We used a strychnine-induced hyperalgesia model of the hot 
plate test and administered muscimol 0.1 µg or baclofen 0.01 µg 
at their maximum doses respectively. We assume that in an ex-
perimental pain model like the one used in the present study, in 
the absence of nerve injury or inflammation, GABA receptors do 
not contribute significantly to such modulation. Possible expla-
nations of this difference may include formalin-induced second 
phase pain that resulted from activation of central sensitized neu-
rons due to peripheral inflammation, while the hot plate test as-
sesses pain reactions involving higher brain centers that are af-
fected by both motor and emotional components. We believe 
that different nociception causes different pain and that the an-
algesic mechanisms of drugs are also different.
  We did not observe any animal showing motor impairment 
or sedative effects after drug injection. According to previous 
studies (18, 20, 24), muscimol produced motor weakness at an-
algesic doses ranges and baclofen impaired performance on the 
rotarod apparatus in the antinociceptive, antiallodynic, and an-
tihyperalgesic dose ranges, suggesting that motor dysfunction 
may have impaired withdrawal from the evocative stimuli, there-
by mimicking antinociception, antiallodynia, and antihyperal-
gesia. Therefore, the lack of antihyperalgesic effects of GABA ag-
onists at doses producing motor dysfunction is consistent with 
the limited effectiveness of them observed in many clinical stud-
ies of neuropathic pain. We can not suggest that the reason of 
the lack of antihyperalgesic effects of GABA agonists is resulted 
from only the lack of interaction with glycine receptor because 
of we did not perform an experiment of co-administration of 
glycine and GABA agonist to determine the pharmacological 
interaction of two receptors. 
  In summary, glycine reduces strychnine-induced thermal hy-
peralgesia responses in vivo. The inhibitory effects of muscimol 
or baclofen on strychnine-induced thermal hyperalgesia are not 
observed. Thus, GABA receptor agonists may lack the binding 
abilities of glycine receptor antagonists with their sites in the 
central nervous system.
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AUTHOR SUMMARY
Pharmacology of Intracisternal or Intrathecal Glycine, Muscimol, and Baclofen in 
Strychnine-induced Thermal Hyperalgesia of Mice
Il Ok Lee, Jin Kuk Son, Eui-Sung Lim and Yeon-Soo Kim 
The present study demonstrates that glycine receptor antagonists produce thermal hyperalgesia, confirming the hypothesis that 
the loss of endogenous glycine tone leads to hyperalgesia. Muscimol or baclofen was ineffective to reduce strychnine-induced 
thermal hyperalgesia. These results suggest that GABA lacks an antinociceptive effect on the strychnine induced thermal 
hyperalgesia, and GABA receptor agonists may lack the binding abilities of glycine receptors in the central nervous system.